BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. [DOI: 10.1016/s0016-5085(03)00689-9] [Cited by in Crossref: 581] [Cited by in F6Publishing: 257] [Article Influence: 30.6] [Reference Citation Analysis]
Number Citing Articles
1 Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, Ji J. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.Ther Adv Med Oncol. 2019;11:1758835919862692. [PMID: 31384311 DOI: 10.1177/1758835919862692] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
2 Ho M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs. 2011;25:275-284. [PMID: 21942912 DOI: 10.2165/11595360-000000000-00000] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
3 Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol. 2008;4:803-814. [PMID: 19086847 DOI: 10.2217/14796694.4.6.803] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
4 Sun CK, Chua MS, He J, So SK. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia. 2011;13:735-747. [PMID: 21847365 DOI: 10.1593/neo.11664] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
5 Sabry D, Abdelaleem OO, El Amin Ali AM, Mohammed RA, Abdel-Hameed ND, Hassouna A, Khalifa WA. Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study. Mol Biol Rep 2019;46:2039-47. [PMID: 30710234 DOI: 10.1007/s11033-019-04653-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
6 Zhao R, Cheng L, Jiang Z, Wei X, Li B, Wu Q, Wang S, Lin S, Long Y, Zhang X, Wu Y, Du X, Pei D, Liu P, Li Y, Cui S, Yao Y, Li P. DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. Oncoimmunology 2019;8:e1509173. [PMID: 30546945 DOI: 10.1080/2162402X.2018.1509173] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
7 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
8 Wu M, Liu Z, Li X, Zhang A, Li N. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:827-840. [PMID: 32095079 DOI: 10.2147/ott.s229835] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Reghupaty SC, Sarkar D. Current Status of Gene Therapy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1265. [PMID: 31466358 DOI: 10.3390/cancers11091265] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
10 Miyoshi E, Ito Y, Miyoshi Y. Involvement of aberrant glycosylation in thyroid cancer. J Oncol 2010;2010:816595. [PMID: 20652009 DOI: 10.1155/2010/816595] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
11 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.1007/bf03260065] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
12 Bremmer F, Ströbel P, Jarry H, Strecker J, Gaisa N, Strauß A, Schweyer S, Radzun HJ, Behnes CL. CK19 is a sensitive marker for yolk sac tumours of the testis. Diagn Pathol 2015;10:7. [PMID: 25889715 DOI: 10.1186/s13000-015-0243-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
13 Li YC, Yang CS, Zhou WL, Li HS, Han YJ, Wang QS, Wu HB. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. World J Gastroenterol 2018; 24(4): 494-503 [PMID: 29398870 DOI: 10.3748/wjg.v24.i4.494] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
14 Zheng M, Ruan Y, Yang M, Guan Y, Wu Z. The comparative study on ultrastructure and immunohistochemistry in AFP negative and positive hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci 2004;24:547-9, 559. [PMID: 15791836 DOI: 10.1007/BF02911350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Lee NP, Chen L, Lin MC, Tsang FH, Yeung C, Poon RT, Peng J, Leng X, Beretta L, Sun S. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res. 2009;8:1293-1303. [PMID: 19161326 DOI: 10.1021/pr800637z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
16 Gao W, Xu Y, Liu J, Ho M. Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate. Sci Rep 2016;6:26245. [PMID: 27185050 DOI: 10.1038/srep26245] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
17 Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, Kramer J, Duan Z, Yang H, Kolluri A, Hummer AM, Torres MB, Zhu H, Hall MD, Luo X, Chen J, Wang Q, Abate-Daga D, Dropulic B, Hewitt SM, Orentas RJ, Greten TF, Ho M. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology 2020;158:2250-2265.e20. [PMID: 32060001 DOI: 10.1053/j.gastro.2020.02.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
18 Qian L, Huang J, Qin H. Glypican-3-expressing gastric metastasis of hepatocellular carcinoma via curative subtotal gastrectomy: a case report. J Gastrointest Cancer 2014;45 Suppl 1:166-9. [PMID: 24777446 DOI: 10.1007/s12029-014-9613-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Robinson JL, Feizi A, Uhlén M, Nielsen J. A Systematic Investigation of the Malignant Functions and Diagnostic Potential of the Cancer Secretome. Cell Rep 2019;26:2622-2635.e5. [PMID: 30840886 DOI: 10.1016/j.celrep.2019.02.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
20 Tanaka Y, Tateishi R, Koike K. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E3070. [PMID: 30297672 DOI: 10.3390/ijms19103070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
21 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
23 Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008;8:200. [PMID: 18638391 DOI: 10.1186/1471-2407-8-200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
24 Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B, Ho M, Jia S, Ding T, Gao W. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer 2021;9:e001875. [PMID: 33833049 DOI: 10.1136/jitc-2020-001875] [Reference Citation Analysis]
25 Yip CW, Cheung PF, Leung IC, Wong NC, Cheng CK, Fan ST, Cheung ST. Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells. Carcinogenesis 2014;35:2485-94. [PMID: 25115442 DOI: 10.1093/carcin/bgu164] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
26 Kondo F. Assessment of stromal invasion for correct histological diagnosis of early hepatocellular carcinoma. Int J Hepatol 2011;2011:241652. [PMID: 22007311 DOI: 10.4061/2011/241652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Wang CH, Lang ZW, Cheng J, Wu Y, Yang YJ, Zhang LY, Dang XY. Suppression subtractive hybridization for cloning of genes transactivated by RNase H protein of HBV DNA polymerase. Shijie Huaren Xiaohua Zazhi 2004; 12(7): 1564-1568 [DOI: 10.11569/wcjd.v12.i7.1564] [Reference Citation Analysis]
28 Fleming BD, Urban DJ, Hall MD, Longerich T, Greten TF, Pastan I, Ho M. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Hepatology 2020;71:1696-711. [PMID: 31520528 DOI: 10.1002/hep.30949] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
29 Jin GZ, Dong H, Yu WL, Li Y, Lu XY, Yu H, Xian ZH, Dong W, Liu YK, Cong WM. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer. 2013;13:161. [PMID: 23537217 DOI: 10.1186/1471-2407-13-161] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
30 Takahara Y, Takahashi M, Wagatsuma H, Yokoya F, Zhang QW, Yamaguchi M, Aburatani H, Kawada N. Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis. World J Gastroenterol 2006; 12(40): 6473-6499 [PMID: 17072980 DOI: 10.3748/wjg.v12.i40.6473] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
31 Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5:e1129483. [PMID: 27467945 DOI: 10.1080/2162402x.2015.1129483] [Cited by in Crossref: 77] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
32 Yu JP, Xu XG, Ma RJ, Qin SN, Wang CR, Wang XB, Li M, Li MS, Ma Q, Xu WW. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma. J Clin Lab Anal 2015;29:85-93. [PMID: 24687454 DOI: 10.1002/jcla.21733] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
33 van Sprundel RG, van den Ingh TS, Schotanus BA, van Wolferen ME, Penning LC, Rothuizen J, Spee B. Cellular characteristics of keratin 19-positive canine hepatocellular tumours explain its aggressive behaviour. Vet Rec Open 2017;4:e000212. [PMID: 29118993 DOI: 10.1136/vetreco-2016-000212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
35 Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 2008;25:149-59. [PMID: 18027090 DOI: 10.1007/s10585-007-9125-3] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 5.7] [Reference Citation Analysis]
36 Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology. 2017;6:e1346764. [PMID: 29123959 DOI: 10.1080/2162402x.2017.1346764] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
37 Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747-2759. [PMID: 32449239 DOI: 10.1111/cas.14497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Jeon Y, Jang ES, Choi YS, Kim JW, Jeong SH. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clin Mol Hepatol. 2016;22:359-365. [PMID: 27729630 DOI: 10.3350/cmh.2016.0033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
39 Chen JJ, Xie CM, Wang CR, Wan Y, Dong ZN, Li M, Xu WW. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. J Fluoresc. 2017;27:1479-1485. [PMID: 28429175 DOI: 10.1007/s10895-017-2087-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y, Fang-yin Z, Da-yong Z, Rong-cheng L. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep. 2012;39:351-357. [PMID: 21655958 DOI: 10.1007/s11033-011-0745-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
41 Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocell Carcinoma. 2016;3:63-67. [PMID: 27878117 DOI: 10.2147/jhc.s116513] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
42 Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-10583 [PMID: 26457017 DOI: 10.3748/wjg.v21.i37.10573] [Cited by in CrossRef: 188] [Cited by in F6Publishing: 182] [Article Influence: 26.9] [Reference Citation Analysis]
43 Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Reference Citation Analysis]
44 Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2020;111:334-42. [PMID: 31774932 DOI: 10.1111/cas.14251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
45 Yang X, Liu H, Sun CK, Natarajan A, Hu X, Wang X, Allegretta M, Guttmann RD, Gambhir SS, Chua MS, Cheng Z, So SK. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials 2014;35:6964-71. [PMID: 24836949 DOI: 10.1016/j.biomaterials.2014.04.089] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
46 Zhang B, Finn RS. Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer. 2016;5:221-232. [PMID: 27493897 DOI: 10.1159/000367763] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
47 Zhang QY, Chen H, Lin Z, Lin JM. Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3. J Pharm Anal 2011;1:166-74. [PMID: 29403695 DOI: 10.1016/j.jpha.2011.06.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
48 Xu Y, Li H, Gao RL, Adeyemo O, Itkin M, Kaplan DE. Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clin Immunol 2011;139:302-13. [PMID: 21419713 DOI: 10.1016/j.clim.2011.02.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
49 Shih TC, Wang L, Wang HC, Wan YY. Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Res 2020;4:168-72. [PMID: 33384879 DOI: 10.1016/j.livres.2020.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, Matsumura T, Yanagawa T, Ito T, Imawari M. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2010;45:451-458. [PMID: 19936602 DOI: 10.1007/s00535-009-0155-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 5.5] [Reference Citation Analysis]
51 Kurahashi T, Yoshida Y, Ogura S, Egawa M, Furuta K, Hikita H, Kodama T, Sakamori R, Kiso S, Kamada Y, Wang IC, Eguchi H, Morii E, Doki Y, Mori M, Kalinichenko VV, Tatsumi T, Takehara T. Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice. Cell Mol Gastroenterol Hepatol 2020;9:425-46. [PMID: 31669262 DOI: 10.1016/j.jcmgh.2019.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
52 Zheng X, Ma W, Sun R, Yin H, Lin F, Liu Y, Xu W, Zeng H. Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity. Redox Biol 2018;14:237-49. [PMID: 28965082 DOI: 10.1016/j.redox.2017.09.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
53 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol 2014; 20(30): 10249-10261 [PMID: 25132742 DOI: 10.3748/wjg.v20.i30.10249] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
55 Wang T, Wang FM, Gao YT, Zhu ZY, Guo HS, Yang B, Zhang CS, Zhang Q, Du Z. Significance of GPC3 expression in liver biopsy specimens for differential diagnosis of liver diseases. Shijie Huaren Xiaohua Zazhi 2011; 19(7): 693-699 [DOI: 10.11569/wcjd.v19.i7.693] [Reference Citation Analysis]
56 Ji F, Fu S, Guo Z, Pang H, Chen D, Wang X, Ju W, Wang D, He X, Hua Y, Peng B. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget. 2016;7:72276-72289. [PMID: 27472390 DOI: 10.18632/oncotarget.10848] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
57 Carrasquillo JA, O'Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, Larson SM, Smith-Jones PM, Lyashchenko SK, Ohishi N, Ohtomo T, Abou-Alfa GK. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res 2018;8:20. [PMID: 29508107 DOI: 10.1186/s13550-018-0374-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
59 Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, Konishi M, Takahashi S, Gotohda N, Suto K, Yoshida T, Nakatsura T. Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncol Lett 2020;19:2657-66. [PMID: 32218816 DOI: 10.3892/ol.2020.11371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Capurro M, Shi W, Izumikawa T, Kitagawa H, Filmus J. Processing by convertases is required for glypican-3-induced inhibition of Hedgehog signaling. J Biol Chem 2015;290:7576-85. [PMID: 25653284 DOI: 10.1074/jbc.M114.612705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
61 Sheng SL, Wang Q, Huang G, Yu B, Qin WX. Simultaneous determination of alpha-fetoprotein immune complexes and alpha-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays. J Clin Lab Anal 2009;23:179-85. [PMID: 19455631 DOI: 10.1002/jcla.20316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
62 Shiota G, Miura N. Biomarkers for hepatocellular carcinoma. Clin J Gastroenterol 2012;5:177-82. [PMID: 26182317 DOI: 10.1007/s12328-012-0301-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
63 Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 275-283 [PMID: 26755876 DOI: 10.3748/wjg.v22.i1.275] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
64 Ismail MH. Glypican-3-Expressing Hepatocellular Carcinoma in a Non-Cirrhotic Patient with Nonalcoholic Steatohepatitis: Case Report and Literature Review. Gastroenterology Res 2010;3:223-8. [PMID: 27957002 DOI: 10.4021/gr224w] [Reference Citation Analysis]
65 Yi B, Wu T, Zhu N, Huang Y, Yang X, Yuan L, Wu Y, Liang X, Jiang X. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma. J Nanobiotechnology 2021;19:74. [PMID: 33726759 DOI: 10.1186/s12951-021-00818-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Senes G, Fanni D, Cois A, Uccheddu A, Faa G. Intratumoral sampling variability in hepatocellular carcinoma: A case report. World J Gastroenterol 2007; 13(29): 4019-4021 [PMID: 17663522 DOI: 10.3748/wjg.v13.i29.4019] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
67 Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y; Precision Liver Cancer Prevention Consortium. Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine 2018;14:317-25. [PMID: 29157977 DOI: 10.1016/j.nano.2017.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
68 Guo X, Jiang H, Shi B, Zhou M, Zhang H, Shi Z, Du G, Luo H, Wu X, Wang Y, Sun R, Li Z. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Front Pharmacol. 2018;9:1118. [PMID: 30327605 DOI: 10.3389/fphar.2018.01118] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
69 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
70 Zhang YF, Ho M. Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. Sci Rep 2016;6:33878. [PMID: 27667400 DOI: 10.1038/srep33878] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
71 Bi Y, Jiang H, Wang P, Song B, Wang H, Kong X, Li Z. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager. Oncotarget 2017;8:52866-76. [PMID: 28881778 DOI: 10.18632/oncotarget.17905] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
72 He L, Zhang Y, Chen J, Liu G, Zhu J, Li X, Li D, Yang Y, Lee CS, Shi J, Yin C, Lai P, Wang L, Fang C. A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. J Mater Chem B 2021;9:8779-92. [PMID: 34635903 DOI: 10.1039/d1tb01729b] [Reference Citation Analysis]
73 Gu Q, Yu X, Chen H, Chen G. Clinicopathological features of combined hepatocellular-cholangiocarcinoma with sarcomatous change: Case report and literature review. Medicine (Baltimore) 2018;97:e9640. [PMID: 29504997 DOI: 10.1097/MD.0000000000009640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
74 Wu F, Wu B, Zhang X, Yang C, Zhou C, Ren S, Wang J, Yang Y, Wang G. Screening of MicroRNA Related to Irradiation Response and the Regulation Mechanism of miRNA-96-5p in Rectal Cancer Cells. Front Oncol 2021;11:699475. [PMID: 34458143 DOI: 10.3389/fonc.2021.699475] [Reference Citation Analysis]
75 Chiba T, Suzuki E, Saito T, Ogasawara S, Ooka Y, Tawada A, Iwama A, Yokosuka O. Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2020-2028 [PMID: 26261691 DOI: 10.4254/wjh.v7.i16.2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
76 Nguyen TB, Roncalli M, Di Tommaso L, Kakar S. Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma. Mod Pathol. 2016;29:283-292. [PMID: 26769138 DOI: 10.1038/modpathol.2015.162] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
77 Elsayed MMA, Okda TM, Atwa GMK, Omran GA, Abd Elbaky AE, Ramadan AEH. Design and Optimization of Orally Administered Luteolin Nanoethosomes to Enhance Its Anti-Tumor Activity against Hepatocellular Carcinoma. Pharmaceutics 2021;13:648. [PMID: 34063274 DOI: 10.3390/pharmaceutics13050648] [Reference Citation Analysis]
78 Waaijer SJ, Giesen D, Ishiguro T, Sano Y, Sugaya N, Schröder CP, de Vries EG, Lub-de Hooge MN. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. J Immunother Cancer 2020;8:e000548. [PMID: 32217763 DOI: 10.1136/jitc-2020-000548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
79 Houvast RD, Vankemmelbeke M, Durrant LG, Wuhrer M, Baart VM, Kuppen PJK, de Geus-Oei LF, Vahrmeijer AL, Sier CFM. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers (Basel) 2020;12:E3870. [PMID: 33371487 DOI: 10.3390/cancers12123870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Vongchan P, Linhardt RJ. Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2. World J Hepatol 2017; 9(7): 368-384 [PMID: 28321273 DOI: 10.4254/wjh.v9.i7.368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
81 Kondo F. Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application : Hepatocellular carcinoma. Hepatol Int 2009;3:283-93. [PMID: 19669379 DOI: 10.1007/s12072-008-9107-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
82 Wee A. Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations. Patholog Res Int 2011;2011:587936. [PMID: 21789263 DOI: 10.4061/2011/587936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
83 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
84 Zhang W, Hu Z, Tian J, Fang C. A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. Ann Transl Med 2021;9:171. [PMID: 33569473 DOI: 10.21037/atm-20-5341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
86 Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K, Zheng X, Liu J, Su M, Liu P, Jia W. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 2016;139:1764-75. [PMID: 27273788 DOI: 10.1002/ijc.30219] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 14.5] [Reference Citation Analysis]
87 Guo J, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Ther. 2021;. [PMID: 33500535 DOI: 10.1038/s41417-020-00259-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, Loffredo CA, Forgues M, Huang H, Xing XJ. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19:3944-3954. [PMID: 23719264 DOI: 10.1158/1078-0432.ccr-12-3363] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
89 Fanni D, Nemolato S, Ganga R, Senes G, Gerosa C, Van Eyken P, Geboes K, Faa G. Cytokeratin 20-positive hepatocellular carcinoma. Eur J Histochem 2009;53:e32. [PMID: 22073364 DOI: 10.4081/ejh.2009.e32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
90 Kimura A, Sogawa K, Satoh M, Kodera Y, Yokosuka O, Tomonaga T, Nomura F. The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma. Int J Proteomics 2012;2012:623190. [PMID: 22957256 DOI: 10.1155/2012/623190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
91 Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011;15:1013-1031. [PMID: 21155971 DOI: 10.1111/j.1582-4934.2010.01236.x] [Cited by in Crossref: 329] [Cited by in F6Publishing: 323] [Article Influence: 29.9] [Reference Citation Analysis]
92 Aydin Y, Koksal AR, Thevenot P, Chava S, Heidari Z, Lin D, Sandow T, Moroz K, Parsi MA, Scott J, Cohen A, Dash S. Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. JHC 2021;Volume 8:1579-96. [DOI: 10.2147/jhc.s327339] [Reference Citation Analysis]
93 Liao H, Xiong T, Peng J, Xu L, Liao M, Zhang Z, Wu Z, Yuan K, Zeng Y. Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning. Ann Surg Oncol. 2020;27:2359-2369. [PMID: 31916093 DOI: 10.1245/s10434-019-08190-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
94 Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, Suzuki I, Yamamoto S, Furuse J. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci. 2014;105:455-462. [PMID: 24521523 DOI: 10.1111/cas.12368] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
95 Sangro B, Palmer D, Melero I. Immunotherapy of hepatocellular carcinoma. Hepat Oncol 2014;1:433-46. [PMID: 30190978 DOI: 10.2217/hep.14.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
96 Zhao P, Yang X, Qi S, Liu H, Jiang H, Hoppmann S, Cao Q, Chua MS, So SK, Cheng Z. Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes. Biomed Res Int 2013;2013:759057. [PMID: 23710458 DOI: 10.1155/2013/759057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
97 Yu J, Wang YJ, Gao YT, Shi WX, Wang QH, Liu T, Xu YJ, Yang B, Du Z. Detection of HCC-associated gene expression by real-time fluorescence quantitative PCR to establish a molecular diagnostic index for HCC. Shijie Huaren Xiaohua Zazhi 2011; 19(6): 588-595 [DOI: 10.11569/wcjd.v19.i6.588] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Zhang Y, Zhao J, Cai J, Ye JC, Xiao YT, Mei Y, Zeng MS, Xie CM, Jiang Y, Feng GK. Integrin α6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice. Mol Imaging Biol 2020;22:864-72. [PMID: 31792839 DOI: 10.1007/s11307-019-01437-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Couchman JR, Multhaupt H, Sanderson RD. Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer. F1000Res 2016;5:F1000 Faculty Rev-1541. [PMID: 27408707 DOI: 10.12688/f1000research.8543.1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
100 Wang S, Kalim M, Liang K, Zhan J. Polyclonal antibody production against rGPC3 and their application in diagnosis of hepatocellular carcinoma. Prep Biochem Biotechnol 2018;48:435-45. [PMID: 29561231 DOI: 10.1080/10826068.2018.1452258] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
102 Feng S, Meng X, Li Z, Chang TS, Wu X, Zhou J, Joshi B, Choi EY, Zhao L, Zhu J, Wang TD. Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma. J Med Chem 2021;64:15639-50. [PMID: 34590489 DOI: 10.1021/acs.jmedchem.1c00697] [Reference Citation Analysis]
103 Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 2013;19:6678-6685. [PMID: 24030702 DOI: 10.1158/1078-0432.ccr-13-1721] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
104 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 9.5] [Reference Citation Analysis]
105 Toyoda H, Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis. Nephrol Dial Transplant 2021;36:1097-103. [PMID: 33009910 DOI: 10.1093/ndt/gfaa165] [Reference Citation Analysis]
106 Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol 2014;49:117-25. [PMID: 23532638 DOI: 10.1007/s00535-013-0793-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
107 Machairas N, Tsilimigras DI, Moris D. CD24 as a Novel Predictive Biomarker in Patients with Hepatocellular Carcinoma: Friend or Foe? J Invest Surg 2020;33:542-3. [PMID: 30574819 DOI: 10.1080/08941939.2018.1538399] [Reference Citation Analysis]
108 Leung M, Kievit FM, Florczyk SJ, Veiseh O, Wu J, Park JO, Zhang M. Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance. Pharm Res 2010;27:1939-48. [PMID: 20585843 DOI: 10.1007/s11095-010-0198-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 5.2] [Reference Citation Analysis]
109 Ikeda A, Nagayama S, Yamamoto N, Akiyoshi T, Konishi T, Fujimoto Y, Fukunaga Y, Ishikawa Y, Ueno M. A rare case of hepatocellular carcinoma metastasizing hematogenously to the rectum. Int Cancer Conf J 2016;5:168-73. [PMID: 31149448 DOI: 10.1007/s13691-016-0251-0] [Reference Citation Analysis]
110 Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. Int J Nanomedicine 2016;11:5645-69. [PMID: 27920520 DOI: 10.2147/IJN.S115727] [Cited by in Crossref: 67] [Cited by in F6Publishing: 25] [Article Influence: 11.2] [Reference Citation Analysis]
111 Zhang H, Zhu C, Zhao Y, Li M, Wu L, Yang X, Wan X, Wang A, Zhang MQ, Sang X, Zhao H. Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. Oncotarget 2015;6:43770-8. [PMID: 26540467 DOI: 10.18632/oncotarget.6087] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
112 Meng P, Zhang YF, Zhang W, Chen X, Xu T, Hu S, Liang X, Feng M, Yang X, Ho M. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Sci Rep 2021;11:40. [PMID: 33420124 DOI: 10.1038/s41598-020-79524-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Lam M, Reales-Calderon JA, Ow JR, Adriani G, Pavesi A. In vitro 3D liver tumor microenvironment models for immune cell therapy optimization. APL Bioeng 2021;5:041502. [PMID: 34632251 DOI: 10.1063/5.0057773] [Reference Citation Analysis]
114 Nishida T, Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31510063 DOI: 10.3390/cancers11091339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
115 Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Alavian SM, Lankarani KB, Farrokh P, Randel Nyengaard J. Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity. Eur J Histochem 2018;62:2859. [PMID: 29569872 DOI: 10.4081/ejh.2018.2859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
116 Hagag NA, Ali YBM, Elsharawy AA, Talaat RM. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression. J Gastrointest Cancer. 2020;51:234-241. [PMID: 31028536 DOI: 10.1007/s12029-019-00234-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
117 Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M, Shirakawa H, Nobuoka D, Nakatsura T. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican3derived peptide. Int J Oncol. 2013;43:1019-1026. [PMID: 23903757 DOI: 10.3892/ijo.2013.2044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
118 Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, Yeung RS, Minoshima S, Park JO. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med 2014;55:799-804. [PMID: 24627434 DOI: 10.2967/jnumed.113.132118] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
119 Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagn Pathol 2010;5:64. [PMID: 20868507 DOI: 10.1186/1746-1596-5-64] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
120 Zhao M, Liu Z, Dong L, Zhou H, Yang S, Wu W, Lin J. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma. Int J Nanomedicine. 2018;13:4433-4443. [PMID: 30122918 DOI: 10.2147/ijn.s168268] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
121 Li B, Liu H, Shang HW, Li P, Li N, Ding HG. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci. 2013;13:703-709. [PMID: 24250310 DOI: 10.4314/ahs.v13i3.26] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
122 Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, Zhang C. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem. 2013;61:639-648. [PMID: 23686365 DOI: 10.1369/0022155413492771] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
123 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
124 Hoenerhoff MJ, Pandiri AR, Lahousse SA, Hong HH, Ton TV, Masinde T, Auerbach SS, Gerrish K, Bushel PR, Shockley KR, Peddada SD, Sills RC. Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: similarities in the molecular landscape with human liver cancer. Toxicol Pathol 2011;39:678-99. [PMID: 21571946 DOI: 10.1177/0192623311407213] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
125 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Reference Citation Analysis]
126 Luo FB, Zhang KH. Advances in the relationship between glypican-3 and primary hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 155-159 [DOI: 10.11569/wcjd.v18.i2.155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J, He Z, Liu J, Zheng S, Luo Y. Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial. EBioMedicine. 2017;24:56-63. [PMID: 28939487 DOI: 10.1016/j.ebiom.2017.09.007.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Yuan H, Wang J, Wang F, Zhang N, Li Q, Xie F, Chen T, Zhai R, Wang F, Guo Y, Ni W, Tai G. Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Mol Med Rep 2015;12:6782-8. [PMID: 26398332 DOI: 10.3892/mmr.2015.4323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
129 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Meer SV, Man RA, Siersema PD, Erpecum KJV. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013; 19(40): 6744-6756 [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
131 Fleming BD, Ho M. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. Biomolecules 2020;10:E934. [PMID: 32575752 DOI: 10.3390/biom10060934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer. 2016;8:37-55. [PMID: 27398029 DOI: 10.4137/bic.s34413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
133 Capurro MI, Shi W, Filmus J. LRP1 mediates Hedgehog-induced endocytosis of the GPC3-Hedgehog complex. J Cell Sci 2012;125:3380-9. [PMID: 22467855 DOI: 10.1242/jcs.098889] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
134 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2016; 22(37): 8271-8282 [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
135 Di Tommaso L, Roncalli M. Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How. Front Med (Lausanne). 2017;4:10. [PMID: 28280721 DOI: 10.3389/fmed.2017.00010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
136 Hashimoto K, Suzuki AM, Dos Santos A, Desterke C, Collino A, Ghisletti S, Braun E, Bonetti A, Fort A, Qin XY, Radaelli E, Kaczkowski B, Forrest AR, Kojima S, Samuel D, Natoli G, Buendia MA, Faivre J, Carninci P. CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. Genome Res 2015;25:1812-24. [PMID: 26510915 DOI: 10.1101/gr.191031.115] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
137 Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. Hum Vaccin Immunother. 2013;9:1228-1233. [PMID: 23466818 DOI: 10.4161/hv.24179] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
138 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore) 2018;97:e11130. [PMID: 29901640 DOI: 10.1097/MD.0000000000011130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
140 Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012;2012:859076. [PMID: 22655201 DOI: 10.1155/2012/859076] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
141 Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, Wu H, Chen K. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Mol Imaging Biol 2020;22:134-43. [PMID: 31044341 DOI: 10.1007/s11307-019-01356-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
142 Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial Watch: Adoptively transferred cells for anticancer immunotherapy. Oncoimmunology 2017;6:e1363139. [PMID: 29147628 DOI: 10.1080/2162402X.2017.1363139] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
143 Akutsu N, Yamamoto H, Sasaki S, Taniguchi H, Arimura Y, Imai K, Shinomura Y. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol 2010; 16(28): 3521-3528 [PMID: 20653060 DOI: 10.3748/wjg.v16.i28.3521] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
144 Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer. 2019;19:1088. [PMID: 31718608 DOI: 10.1186/s12885-019-6322-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
145 Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2013;110:E1083-E1091. [PMID: 23471984 DOI: 10.1073/pnas.1217868110] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 12.4] [Reference Citation Analysis]
146 Nakajima M, Hazama S, Tamada K, Udaka K, Kouki Y, Uematsu T, Arima H, Saito A, Doi S, Matsui H, Shindo Y, Matsukuma S, Kanekiyo S, Tokumitsu Y, Tomochika S, Iida M, Yoshida S, Nakagami Y, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Nagano H. A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial. Cancer Immunol Immunother 2020;69:1651-62. [PMID: 32219501 DOI: 10.1007/s00262-020-02518-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
147 Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 2012;12:e6122. [PMID: 23162601 DOI: 10.5812/hepatmon.6122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
148 Valsechi MC, Oliveira AB, Conceição AL, Stuqui B, Candido NM, Provazzi PJ, de Araújo LF, Silva WA Jr, Calmon Mde F, Rahal P. GPC3 reduces cell proliferation in renal carcinoma cell lines. BMC Cancer 2014;14:631. [PMID: 25168166 DOI: 10.1186/1471-2407-14-631] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
149 Maruyama H, Yamaguchi T, Nagamatsu H, Shiina S. AI-Based Radiological Imaging for HCC: Current Status and Future of Ultrasound. Diagnostics (Basel) 2021;11:292. [PMID: 33673229 DOI: 10.3390/diagnostics11020292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
150 Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-Generation Cancer Immunotherapy Targeting Glypican-3. Front Oncol 2019;9:248. [PMID: 31024850 DOI: 10.3389/fonc.2019.00248] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
151 Hanaoka H, Nagaya T, Sato K, Nakamura Y, Watanabe R, Harada T, Gao W, Feng M, Phung Y, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol Pharm 2015;12:2151-7. [PMID: 25955255 DOI: 10.1021/acs.molpharmaceut.5b00132] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
152 Henderson JM, Polak N, Chen J, Roediger B, Weninger W, Kench JG, McCaughan GW, Zhang HE, Gorrell MD. Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma. Sci Rep. 2018;8:10283. [PMID: 29980757 DOI: 10.1038/s41598-018-28486-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
153 Jeong SW, Jang JY, Chung RT. Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol. 2012;18:347-356. [PMID: 23323249 DOI: 10.3350/cmh.2012.18.4.347] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
154 Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12(8): 1175-1181 [PMID: 16534867 DOI: 10.3748/wjg.v12.i8.1175] [Cited by in CrossRef: 195] [Cited by in F6Publishing: 183] [Article Influence: 12.2] [Reference Citation Analysis]
155 Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL, Escorcia FE. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules 2020;26:E4. [PMID: 33374953 DOI: 10.3390/molecules26010004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
156 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(11): 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
158 Xie C, Tiede C, Zhang X, Wang C, Li Z, Xu X, McPherson MJ, Tomlinson DC, Xu W. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Sci Rep 2017;7:9608. [PMID: 28852111 DOI: 10.1038/s41598-017-10083-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
159 Chen G, Chen YC, Reis B, Belousov A, Jukofsky L, Rossin C, Muehlig A, Xu C, Essioux L, Ohtomo T, Di Laurenzio L, Puig O, Lee R. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget 2018;9:10436-44. [PMID: 29535817 DOI: 10.18632/oncotarget.23830] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
160 Yılmaz Y, Güneş A, Topel H, Atabey N. Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. J Gastrointest Cancer 2017;48:225-37. [PMID: 28819741 DOI: 10.1007/s12029-017-9958-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
161 Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:1417-1424. [PMID: 23743582 DOI: 10.1007/s00432-013-1458-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
162 Wang WL, Gao YT. Advances in genes and gene interaction of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2008; 16(29): 3289-3294 [DOI: 10.11569/wcjd.v16.i29.3289] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
164 Sa ZQ, Qin JM, Ni L. Role of proteomics in exploring the pathogenesis, diagnosis and treatment of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(15): 1521-1524 [DOI: 10.11569/wcjd.v18.i15.1521] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Jia XL, Li SY, Dang SS, Cheng YA, Zhang X, Wang WJ, Hughes CE, Caterson B. Increased expression of chondroitin sulphate proteoglycans in rat hepatocellular carcinoma tissues. World J Gastroenterol 2012; 18(30): 3962-3976 [PMID: 22912547 DOI: 10.3748/wjg.v18.i30.3962] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
166 Li J, Gao JZ, Du JL, Wei LX. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2014; 20(20): 6336-6344 [PMID: 24876756 DOI: 10.3748/wjg.v20.i20.6336] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
167 Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
168 Wang D, Gao Y, Zhang Y, Wang L, Chen G. Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma. Biosci Rep 2019;39:BSR20181147. [PMID: 31160489 DOI: 10.1042/BSR20181147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
169 Ly K, Essalmani R, Desjardins R, Seidah NG, Day R. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells. J Biol Chem 2016;291:24676-87. [PMID: 27758865 DOI: 10.1074/jbc.M116.746883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
170 Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol 2012; 18(19): 2408-2414 [PMID: 22654434 DOI: 10.3748/wjg.v18.i19.2408] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
171 Xu Q, Li P, Xue P, Zhu WP, Chen RX, Yu X. Effects of thymosin α1 on immune function in perioperative patients with primary liver cancer. Shijie Huaren Xiaohua Zazhi 2005; 13(23): 2748-2751 [DOI: 10.11569/wcjd.v13.i23.2748] [Reference Citation Analysis]
172 Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer. 2011;47:333-338. [PMID: 21112773 DOI: 10.1016/j.ejca.2010.10.024] [Cited by in Crossref: 125] [Cited by in F6Publishing: 121] [Article Influence: 10.4] [Reference Citation Analysis]
173 Zhang H, Wang G, Yang X, Qiu M, Xu L. [Investigation of Gene Expression Profile of A549 Cells after Overexpression of GPC5 
by High Throughput Transcriptome Sequencing]. Zhongguo Fei Ai Za Zhi 2016;19:545-9. [PMID: 27561806 DOI: 10.3779/j.issn.1009-3419.2016.08.11] [Reference Citation Analysis]
174 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
175 Fleming BD, Ho M. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) 2016;8:E274. [PMID: 27669301 DOI: 10.3390/toxins8100274] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
176 Motawi TMK, Sadik NAH, Sabry D, Shahin NN, Fahim SA. rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Sci Rep 2019;9:6868. [PMID: 31053802 DOI: 10.1038/s41598-019-43376-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
177 Sakamoto M. Early HCC: diagnosis and molecular markers. J Gastroenterol 2009;44 Suppl 19:108-11. [PMID: 19148803 DOI: 10.1007/s00535-008-2245-y] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
178 Li J, Qiyu S, Wang T, Jin B, Li N. Improving the Detection of Hepatocellular Carcinoma Using Serum AFP Expression in Combination with GPC3 and Micro-RNA MiR-122 Expression. Open Life Sci 2019;14:53-61. [PMID: 33817137 DOI: 10.1515/biol-2019-0007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
179 Afrin MR, Arumugam S, Pitchaimani V, Karuppagounder V, Thandavarayan RA, Harima M, Hossain CF, Suzuki K, Sone H, Matsubayashi Y, Watanabe K. Le Carbone prevents liver damage in non-alcoholic steatohepatitis-hepatocellular carcinoma mouse model via AMPKα-SIRT1 signaling pathway activation. Heliyon 2021;7:e05888. [PMID: 33490669 DOI: 10.1016/j.heliyon.2020.e05888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Zhou S, O'Gorman MR, Yang F, Andresen K, Wang L. Glypican 3 as a Serum Marker for Hepatoblastoma. Sci Rep 2017;7:45932. [PMID: 28378832 DOI: 10.1038/srep45932] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
181 Jiang L, Xu J, Ni J, Gao X, Zhu Z, Dong D, Wang X, Shi C, Tao X, Dong W, Gao Y. A functional insertion/deletion polymorphism in the proximal promoter of CD3G is associated with susceptibility for hepatocellular carcinoma in Chinese population. DNA Cell Biol 2012;31:1480-5. [PMID: 22731821 DOI: 10.1089/dna.2012.1706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
182 Ahrens TD, Bang-Christensen SR, Jørgensen AM, Løppke C, Spliid CB, Sand NT, Clausen TM, Salanti A, Agerbæk MØ. The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis. Front Cell Dev Biol 2020;8:749. [PMID: 32984308 DOI: 10.3389/fcell.2020.00749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
183 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
184 Zhang C, Liang T, Song J, Jiang S, Qu L, Hou G. Evaluation of macrophage migration inhibitory factor as an imaging marker for hepatocellular carcinoma in murine models. Scand J Gastroenterol 2011;46:720-6. [PMID: 21438767 DOI: 10.3109/00365521.2011.568517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
185 Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol. 2015;46:28-36. [PMID: 25354479 DOI: 10.3892/ijo.2014.2737] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
186 Li J, Cheng ZJ, Liu Y, Yan ZL, Wang K, Wu D, Wan XY, Xia Y, Lau WY, Wu MC, Shen F. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget 2015;6:9551-63. [PMID: 25871387 DOI: 10.18632/oncotarget.3314] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
187 Uthamalingam P, Das A, Behra A, Kalra N, Chawla Y. Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and Non-Cirrhotic Livers. J Clin Exp Hepatol. 2018;8:173-180. [PMID: 29892181 DOI: 10.1016/j.jceh.2017.09.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
188 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Fernández D, Guereño M, Lago Huvelle MA, Cercato M, Peters MG. Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway. J Cancer Res Clin Oncol 2018;144:2399-418. [PMID: 30267212 DOI: 10.1007/s00432-018-2751-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
190 He B, He Y, Shi W, Gong S, Chen X, Xiao J, Gu J, Ding W, Wang Y. Bioinformatics analysis of gene expression alterations in microRNA‑122 knockout mice with hepatocellular carcinoma. Mol Med Rep 2017;15:3681-9. [PMID: 28393247 DOI: 10.3892/mmr.2017.6445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
191 Lo RC, Ng IO. Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res. 2011;23:245-253. [PMID: 23359751 DOI: 10.1007/s11670-011-0245-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
192 Li N, Spetz MR, Ho M. The Role of Glypicans in Cancer Progression and Therapy. J Histochem Cytochem 2020;68:841-62. [PMID: 32623934 DOI: 10.1369/0022155420933709] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
193 Zhou Q, Li Z, Zhou J, Joshi BP, Li G, Duan X, Kuick R, Owens SR, Wang TD. In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. Photoacoustics 2016;4:43-54. [PMID: 27766208 DOI: 10.1016/j.pacs.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
194 Xing M, Wang X, Kiken RA, He L, Zhang JY. Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. Int J Mol Sci 2021;22:6139. [PMID: 34200243 DOI: 10.3390/ijms22116139] [Reference Citation Analysis]
195 Singh U, Hur M, Dorman K, Wurtele ES. MetaOmGraph: a workbench for interactive exploratory data analysis of large expression datasets. Nucleic Acids Res 2020;48:e23. [PMID: 31956905 DOI: 10.1093/nar/gkz1209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
196 Ayoub WS, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. [PMID: 31523283 DOI: 10.1177/1758835919869120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
197 Assy N, Assy N, Samuel N, Lerman A, Nseir W. Approach to Solid Liver Masses in the Cirrhotic Patient. Gastroenterology Res 2009;2:259-67. [PMID: 27956969 DOI: 10.4021/gr2009.10.1314] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
198 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Front Immunol 2021;12:655697. [PMID: 33815418 DOI: 10.3389/fimmu.2021.655697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
199 Abouzed TK, Althobaiti F, Abdelkhlek NA, Eldomany EB, Nasr NE, Sadek KM, El-Shazly SA, Kahilo KA, Dorghamm DA. Antitumor and Antioxidant Activity of S-Methyl Methionine Sulfonium Chloride against Liver Cancer Induced in Wistar Albino Rats by Diethyl Nitrosamine and Carbon Tertrachloride. Int J Environ Res Public Health 2021;18:9726. [PMID: 34574650 DOI: 10.3390/ijerph18189726] [Reference Citation Analysis]
200 Rai V, Abdo J, Alsuwaidan AN, Agrawal S, Sharma P, Agrawal DK. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem 2018;437:13-36. [DOI: 10.1007/s11010-017-3092-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
201 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
202 Liu X, Gao F, Jiang L, Jia M, Ao L, Lu M, Gou L, Ho M, Jia S, Chen F, Gao W. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. J Transl Med 2020;18:295. [PMID: 32746924 DOI: 10.1186/s12967-020-02462-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
203 Ma Farag RM, Alayobi D, A Alsaleh K, Kwon H, El-ansary A, Dawoud EA. Influence of Glypican-3 as Anewly Diagnostic Biomarker in Earlydetection of Hepatocellular Carcinoma among Saudi Patients. Biomed Pharmacol J 2018;11:1789-96. [DOI: 10.13005/bpj/1550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Al-Sharaky DR, Younes SF. Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms. J Clin Diagn Res 2016;10:EC06-10. [PMID: 27134876 DOI: 10.7860/JCDR/2016/18375.7430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
205 Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014;588:377-382. [PMID: 24140348 DOI: 10.1016/j.febslet.2013.10.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
206 Nie JH, Yang T, Li H, Ye HS, Zhong GQ, Li TT, Zhang C, Huang WH, Xiao J, Li Z, He JL, Du BL, Zhang Y, Liu J. Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. J Bone Oncol 2021;30:100391. [PMID: 34611509 DOI: 10.1016/j.jbo.2021.100391] [Reference Citation Analysis]
207 Fu Y, Urban DJ, Nani RR, Zhang YF, Li N, Fu H, Shah H, Gorka AP, Guha R, Chen L, Hall MD, Schnermann MJ, Ho M. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology 2019;70:563-76. [PMID: 30353932 DOI: 10.1002/hep.30326] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
208 Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y, Hebrok M. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009;136:2304-2315.e1-4. [PMID: 19272382 DOI: 10.1053/j.gastro.2009.02.067] [Cited by in Crossref: 127] [Cited by in F6Publishing: 119] [Article Influence: 9.8] [Reference Citation Analysis]
209 Lee CW, Tsai HI, Lee WC, Huang SW, Lin CY, Hsieh YC, Kuo T, Chen CW, Yu MC. Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal? J Clin Med 2019;8:E1736. [PMID: 31635078 DOI: 10.3390/jcm8101736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
210 Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines (Basel) 2020;8:E41. [PMID: 31991677 DOI: 10.3390/vaccines8010041] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Laskowski J, Renner B, Pickering MC, Serkova NJ, Smith-Jones PM, Clambey ET, Nemenoff RA, Thurman JM. Complement factor H-deficient mice develop spontaneous hepatic tumors. J Clin Invest 2020;130:4039-54. [PMID: 32369457 DOI: 10.1172/JCI135105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
212 Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, Mehta M, Levin Y, Shetty J, Tran B, Budhu A, Wang XW. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018;68:127-140. [PMID: 29315726 DOI: 10.1002/hep.29778] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 22.8] [Reference Citation Analysis]
213 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
214 Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44:1012-1024. [PMID: 17006932 DOI: 10.1002/hep.21328] [Cited by in Crossref: 200] [Cited by in F6Publishing: 216] [Article Influence: 12.5] [Reference Citation Analysis]
215 Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. J Cancer. 2020;11:2008-2021. [PMID: 32127929 DOI: 10.7150/jca.39972] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
216 Xue Y, Mars WM, Bowen W, Singhi AD, Stoops J, Michalopoulos GK. Hepatitis C Virus Mimics Effects of Glypican-3 on CD81 and Promotes Development of Hepatocellular Carcinomas via Activation of Hippo Pathway in Hepatocytes. Am J Pathol 2018;188:1469-77. [PMID: 29577937 DOI: 10.1016/j.ajpath.2018.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
217 Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, Sawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget 2017;8:37835-44. [PMID: 28035063 DOI: 10.18632/oncotarget.14271] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
218 Andisheh-Tadbir A, Goharian AS, Ranjbar MA. Glypican-3 Expression in Patients with Oral Squamous Cell Carcinoma. J Dent (Shiraz) 2020;21:141-6. [PMID: 32582830 DOI: 10.30476/DENTJODS.2019.84541.1089] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
219 Yim SH, Chung YJ. An overview of biomarkers and molecular signatures in HCC. Cancers (Basel). 2010;2:809-823. [PMID: 24281095 DOI: 10.3390/cancers2020809] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
220 Lau MY, Han H, Hu J, Ji C. Association of cyclin D and estrogen receptor α36 with hepatocellular adenomas of female mice under chronic endoplasmic reticulum stress. J Gastroenterol Hepatol 2013;28:576-83. [PMID: 23216077 DOI: 10.1111/jgh.12084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
221 Chattopadhyay R, de la Vega P, Paik SH, Murata Y, Ferguson EW, Richie TL, Ooi GT. Early transcriptional responses of HepG2-A16 liver cells to infection by Plasmodium falciparum sporozoites. J Biol Chem 2011;286:26396-405. [PMID: 21652718 DOI: 10.1074/jbc.M111.240879] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
222 Lee HA, Lee YR, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Seo YS. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4687-4696 [PMID: 34366629 DOI: 10.3748/wjg.v27.i28.4687] [Reference Citation Analysis]
223 Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3. [PMID: 17244360 DOI: 10.1186/1479-5876-5-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
224 Lee YS, Ko E, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Kim KH, Kwon SY, Yeon JE, Um SH, Byun KS. Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. J Clin Med 2020;9:E323. [PMID: 31979338 DOI: 10.3390/jcm9020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Yang SL, Fang X, Huang ZZ, Liu XJ, Xiong ZF, Liu P, Yao HY, Li CH. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. Dis Markers. 2014;2014:127831. [PMID: 25378766 DOI: 10.1155/2014/127831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
226 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16(4): 418-424 [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 110] [Article Influence: 9.3] [Reference Citation Analysis]
227 Tweedell RE, Tao D, Hamerly T, Robinson TM, Larsen S, Grønning AGB, Norris AM, King JG, Law HCH, Baumbach J, Bergmann-Leitner ES, Dinglasan RR. The Selection of a Hepatocyte Cell Line Susceptible to Plasmodium falciparum Sporozoite Invasion That Is Associated With Expression of Glypican-3. Front Microbiol 2019;10:127. [PMID: 30891005 DOI: 10.3389/fmicb.2019.00127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
228 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
229 Wan S, Kim TH, Smith KJ, Delaney R, Park GS, Guo H, Lin E, Plegue T, Kuo N, Steffes J, Leu C, Simeone DM, Razimulava N, Parikh ND, Nagrath S, Welling TH. New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma.Sci Rep. 2019;9:18575. [PMID: 31819089 DOI: 10.1038/s41598-019-54960-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
230 Ofuji K, Saito K, Yoshikawa T, Nakatsura T. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2014;1:35-42. [PMID: 27508174 DOI: 10.2147/jhc.s48517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
231 Bao L, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T, Dash S. Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol 2014;96:149-54. [PMID: 24369267 DOI: 10.1016/j.yexmp.2013.12.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
232 Zhang L, Yang Z, Le Trinh T, Teng IT, Wang S, Bradley KM, Hoshika S, Wu Q, Cansiz S, Rowold DJ, McLendon C, Kim MS, Wu Y, Cui C, Liu Y, Hou W, Stewart K, Wan S, Liu C, Benner SA, Tan W. Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution. Angew Chem Int Ed Engl 2016;55:12372-5. [PMID: 27601357 DOI: 10.1002/anie.201605058] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
233 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(18): 2251-2256 [DOI: 10.11569/wcjd.v13.i18.2251] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
234 Yan D, He Q, Chen Y, Wang L, Zhang X. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal 2011;25:113-7. [PMID: 21438004 DOI: 10.1002/jcla.20443] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
235 Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer. 2015;4:126-136. [PMID: 26020034 DOI: 10.1159/000367735] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
236 Zhao J, Hou Y, Yin C, Hu J, Gao T, Huang X, Zhang X, Xing J, An J, Wan S, Li J. Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma. Oncogene 2020;39:1724-38. [PMID: 31740780 DOI: 10.1038/s41388-019-1093-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
237 Li TH, Qin C, Zhao BB, Cao HT, Yang XY, Wang YY, Li ZR, Zhou XT, Wang WB. Identification METTL18 as a Potential Prognosis Biomarker and Associated With Immune Infiltrates in Hepatocellular Carcinoma. Front Oncol 2021;11:665192. [PMID: 34123827 DOI: 10.3389/fonc.2021.665192] [Reference Citation Analysis]
238 Zhang Y, Tang J, Zhou X, Zhu SL, Li LQ. Diagnostic accuracy of midkine for hepatocellular carcinoma: A meta-analysis. Mol Genet Genomic Med 2020;8:e1071. [PMID: 31777190 DOI: 10.1002/mgg3.1071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
239 Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, Narita Y, Ishikawa S, Kikuchi T, Mori M, Hirano K. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis. Int J Mol Sci. 2014;15:6556-6568. [PMID: 24747592 DOI: 10.3390/ijms15046556] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
240 Falahi S, Rafiee-Pour HA, Zarejousheghani M, Rahimi P, Joseph Y. Non-Coding RNA-Based Biosensors for Early Detection of Liver Cancer. Biomedicines 2021;9:964. [PMID: 34440168 DOI: 10.3390/biomedicines9080964] [Reference Citation Analysis]
241 Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141-152. [PMID: 23430399 DOI: 10.1007/s00795-013-0016-1] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 18.4] [Reference Citation Analysis]
242 Castillo LF, Tascón R, Lago Huvelle MR, Novack G, Llorens MC, Dos Santos AF, Shortrede J, Cabanillas AM, Bal de Kier Joffé E, Labriola L, Peters MG. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells. Oncotarget 2016;7:60133-54. [PMID: 27507057 DOI: 10.18632/oncotarget.11107] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
243 Kawashima I, Kawashima Y, Matsuoka Y, Fujise K, Sakai H, Takahashi M, Yoshikawa T, Nakatsura T, Ishihara T, Ohno T. Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3. Clin Case Rep 2015;3:444-7. [PMID: 26185646 DOI: 10.1002/ccr3.279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
244 Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel) 2020;12:E1734. [PMID: 32610709 DOI: 10.3390/cancers12071734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
245 Lee KA, Ahn JY, Lee SH, Singh Sekhon S, Kim DG, Min J, Kim YH. Aptamer-based Sandwich Assay and its Clinical Outlooks for Detecting Lipocalin-2 in Hepatocellular Carcinoma (HCC). Sci Rep 2015;5:10897. [PMID: 26039737 DOI: 10.1038/srep10897] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
246 Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2010;4:396-405. [PMID: 20305756 DOI: 10.1007/s12072-009-9157-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
247 Luo C, Shibata K, Suzuki S, Kajiyama H, Senga T, Koya Y, Daimon M, Yamashita M, Kikkawa F. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth. Oncol Rep 2014;32:913-21. [PMID: 24992906 DOI: 10.3892/or.2014.3300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
248 Phung Y, Gao W, Man YG, Nagata S, Ho M. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs. 2012;4:592-599. [PMID: 22820551 DOI: 10.4161/mabs.20933] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
249 Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson DR, Robertson K, Ostrov D, Rameshwar P, Xia CQ, Liu C. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Mol Ther 2017;25:2299-308. [PMID: 28865999 DOI: 10.1016/j.ymthe.2017.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
250 Andreana L, Isgrò G, Pleguezuelo M, Germani G, Burroughs AK. Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol 2009; 1(1): 48-61 [PMID: 21160965 DOI: 10.4254/wjh.v1.i1.48] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
251 Zhang L, Guo Y, Li B, Qu J, Zang C, Li F, Wang Y, Pang H, Li S, Liu Q. Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. Eur J Med Res 2013;18:35. [PMID: 24083576 DOI: 10.1186/2047-783X-18-35] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
252 Han HH, Qiu YJ, Shi YY, Wen W, He XP, Dong LW, Tan YX, Long YT, Tian H, Wang HY. Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe. Theranostics 2018;8:3268-74. [PMID: 29930728 DOI: 10.7150/thno.24711] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
253 West MB, Hanigan MH. γ-Glutamyl transpeptidase is a heavily N-glycosylated heterodimer in HepG2 cells. Arch Biochem Biophys 2010;504:177-81. [PMID: 20831856 DOI: 10.1016/j.abb.2010.08.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
254 Hanaoka H, Nakajima T, Sato K, Watanabe R, Phung Y, Gao W, Harada T, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine (Lond) 2015;10:1139-47. [PMID: 25929570 DOI: 10.2217/nnm.14.194] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
255 Li Y, Yang P. GPC5 gene and its related pathways in lung cancer. J Thorac Oncol 2011;6:2-5. [PMID: 21178712 DOI: 10.1097/JTO.0b013e3181fd6b04] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
256 Li Y, Siegel DL, Scholler N, Kaplan DE. Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library. BMC Biotechnol 2012;12:23. [PMID: 22564378 DOI: 10.1186/1472-6750-12-23] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
257 Gong L, Zheng M, Li Y, Zhang W, Bu W, Shi L, Yan H. Seminal vesicle metastasis after partial hepatectomy for hepatocellular carcinoma. BMC Cancer. 2011;11:111. [PMID: 21443783 DOI: 10.1186/1471-2407-11-111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
258 Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J, He Z, Zheng S, Luo Y. Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial. EBioMedicine. 2017;24:56-63. [PMID: 28939487 DOI: 10.1016/j.ebiom.2017.09.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
259 O'Beirne J, Farzaneh F, Harrison PM. Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes. J Exp Clin Cancer Res 2010;29:48. [PMID: 20465843 DOI: 10.1186/1756-9966-29-48] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
260 Dahlgren D, Lennernäs H. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules 2020;25:E2861. [PMID: 32575828 DOI: 10.3390/molecules25122861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Filmus J, Capurro M, Rast J. Glypicans. Genome Biol. 2008;9:224. [PMID: 18505598 DOI: 10.1186/gb-2008-9-5-224] [Cited by in Crossref: 346] [Cited by in F6Publishing: 338] [Article Influence: 24.7] [Reference Citation Analysis]
262 Baghy K, Tátrai P, Regős E, Kovalszky I. Proteoglycans in liver cancer. World J Gastroenterol 2016; 22(1): 379-393 [PMID: 26755884 DOI: 10.3748/wjg.v22.i1.379] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
263 Xu J, Hong J, Wang Y, Zhou L, Xu B, Si Y, He Y, Chen Y. Prognostic Influence of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies. Front Surg 2021;8:769233. [PMID: 34869566 DOI: 10.3389/fsurg.2021.769233] [Reference Citation Analysis]
264 Mu H, Lin KX, Zhao H, Xing S, Li C, Liu F, Lu HZ, Zhang Z, Sun YL, Yan XY, Cai JQ, Zhao XH. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J Gastroenterol 2014; 20(19): 5826-5838 [PMID: 24914343 DOI: 10.3748/wjg.v20.i19.5826] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
265 Ozkan H, Erdal H, Koçak E, Tutkak H, Karaeren Z, Yakut M, Köklü S. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal. 2011;25:350-353. [PMID: 21919070 DOI: 10.1002/jcla.20484] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
266 Yu L, Yang X, Huang N, Wu M, Sun H, He Q, Lang Q, Zou X, Liu Z, Wang J, Ge L. Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors. Invest New Drugs 2021;39:615-26. [PMID: 33215325 DOI: 10.1007/s10637-020-01033-x] [Reference Citation Analysis]
267 Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016;7:69916-69926. [PMID: 27655712 DOI: 10.18632/oncotarget.12066] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]